Armata Pharmaceuticals (ARMP) Common Equity (2013 - 2026)

Armata Pharmaceuticals has disclosed Common Equity across 14 years of filings, most recently posting -$311.6 million for Q1 2026.

• Common Equity for Q1 2026 came in at -$311.6 million, down 479.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$311.6 million (down 479.34% YoY), and the FY2025 annual result was -$218.6 million, down 355.23% from the prior year.
• Common Equity came in at -$311.6 million for Q1 2026 at Armata Pharmaceuticals, down from -$218.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $61.5 million in Q1 2022 to a low of -$311.6 million in Q1 2026.
• The 5-year median for Common Equity is -$46.1 million (2024), against an average of -$44.5 million.
• Across the five-year window, Common Equity surged 91.86% in 2022 and plunged 479.34% in 2026, its largest moves.
• Armata Pharmaceuticals' Common Equity stood at $36.1 million in 2022, then slumped by 188.87% to -$32.1 million in 2023, then sank by 49.76% to -$48.0 million in 2024, then slumped by 355.23% to -$218.6 million in 2025, then slumped by 42.54% to -$311.6 million in 2026.
• The last three Common Equity figures came in at -$311.6 million (Q1 2026), -$218.6 million (Q4 2025), and -$95.6 million (Q3 2025), per Business Quant data.